that proctitis often extends proximally and can progress to total colitis. 10 Proximal disease extension appears to carry a poor prognosis, not only because it implies a higher disease burden for the individual patient, with higher therapeutic requirements, but also because it is associated with a more severe course. This was originally suggested in population-based inception cohorts, where disease extension was associated with a higher rate of colectomy. 1 Patients with proximal extension following a period of stable proctitis or left-sided disease had (after extension) higher colectomy rates, higher need for biologics, more active disease, and increased hospitalisations than controls who started off with extensive colitis.
11
Few clinical or pathological factors which predict likelihood of disease extension have emerged from prior studies. Young age at diagnosis, extra-intestinal manifestations, refractory disease and nonsmoking have all been proposed as risk factors, but these findings have been inconsistent. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] We therefore performed a systematic review and meta-analysis to identify the rates of extension in patients diagnosed with proctitis or left-sided UC and to examine several risk factors which may be associated with disease extension.
2 | ME TH ODS
| Literature search
This study was conducted according to the recommendations of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. 23 
| Search strategy and study selection
A comprehensive search strategy was designed and executed in PubMed/MEDLINE, Embase, and Scopus to identify all epidemiological studies reporting on extension of ulcerative colitis. The search query employed both an exhaustive list of keywords and index terminology whenever possible. Animal studies were excluded as recommended in the Cochrane Handbook of Systematic Reviews of
Interventions. 24 No date or language filters were employed in the search, although subsequently all articles not written in English, French, Italian, Greek, Spanish, Catalan or Portuguese were excluded. The full search strategy for each database is reported in Table S1 .
All studies identified by the electronic searches were independently screened by two reviewers (GR and KK). In the case of disagreement between the two reviewers, a third author (JT) was consulted. If the study title and/or abstract clearly indicated that the study did not meet the pre-defined selection criteria, it was excluded from further analysis. The remaining results were assessed for inclusion based on the full text of the article. Reviewers sought to identify epidemiological studies, including cohort, longitudinal, casecontrol and other observational studies reporting on extension of ulcerative colitis. Studies which did not include a baseline endoscopic assessment were excluded. Figure 1 is a flow chart outlining the study-selection process.
The following data were extracted from those studies which met the eligibility criteria: general study information including the name of the first author, year of publication, full title, and outcomes of interest as specified below.
| Inclusion and exclusion criteria
Participants of all ages previously diagnosed with UC using standard clinical, endoscopic, radiological and histologic criteria were considered eligible for inclusion in this review. Due to the expected heterogeneity in diagnostic criteria and assessment of disease activity, any study using a commonly accepted method to diagnose or assess UC was considered for inclusion in this review. We excluded studies in which UC extension was not reported as well as studies with no baseline endoscopic assessment, less than 10 cases or with insufficient information on patients. Moreover, studies showing only preliminary data were excluded.
| Outcomes of interest
The primary outcome of our meta-analysis was the overall extension rate. Secondary outcomes were extension of disease defined as extension of E1 to E2, E2 to E3 or E1 to E3, the cumulative extension at 5 and 10 years, and the clinical factors that were associated with the primary outcome. Geographic location of the studies was also extracted. We also documented study design, patient population when reported (paediatric vs adult), accrual period, and follow-up length. With regard to risks factors of extension, we extracted the following information: therapy pre-extension (local therapy with 5-ASA enemas/suppositories, or steroids enemas, systematic 5-ASA, azathioprine, methotrexate, anti-TNFa, other biological, AZA+anti-TNFa, methotrexate+anti-TNFa, other immunosuppressant, steroids); EIMs including skin, muskuloskeletal, eyes, or primary sclerosing cholangitis (PSC), tobacco usage and age at diagnosis.
| Study quality
The quality of nonrandomised studies was assessed using the Newcastle-Ottawa scale, a tool that allows for quality appraisal of nonrandomised studies in meta-analyses. 25 Detailed results from the quality assessment are provided in Table S2 .
| Statistical analysis
Data from studies were pooled if the studies provided sufficient information for meta-analysis. information on patients were excluded. One study reporting preliminary data from an early cohort of patients was excluded. 41 We conducted a systematic review on 41 studies. Eleven of these studies lacked sufficient information for inclusion in the metaanalysis. A final cohort of 30 unique studies were used for the meta-analysis (Figure 1 ). Information on extension over time (at 5 and 10 years) was reported in 11 studies, 1, 5, 14, 18, 27, 37, 51, 53, 54, 57, 59 of which 3 5, 18, 59 were not included in the meta-analysis because of insufficient information.
Treatments prior to extension were reported in 15 studies 12, 13, 26, [28] [29] [30] [31] 36, 37, 39, 42, 45, 48, 57, 58 with use of steroids in 13 studies. EIMs were reported in seven 
| Meta-analysis
We performed a meta-analysis on a final cohort of 30 unique studies. Meta-analyses were performed for overall rate of extension, E1/E2 to E2/E3 rate of extension, and how extension varies based on age at diagnosis and geographic area was examined. Too few studies reported on other risk factors such as tobacco usage, treatment prior to extension and EIMs to perform any significant analyses on these risk factors.
| Rates of extension
Overall rate of extension was reported in 31 studies including one early cohort of patients that was excluded from the metaanalysis. 42 The overall pooled frequency of UC extension was 
| Age at diagnosis
We performed a sub-analysis by age at diagnosis for the 13 studies where this information was available based on overall extension data ( Figure 4 ). Studies were analysed by dichotomising and comparing the three studies which contained patients younger than 18 years old and the 11 studies including patients older than 18 years. 
| Study quality and publication bias
The chi-squared test for heterogeneity revealed a value of 27.0, and the I 2 test result was 97.7%, indicating significant variability in effect estimates that is likely due to heterogeneity rather than chance.
Egger's test showed no evidence of publication bias (Egger's t-value=1.99, P=.057).
| DISCUSSION
We performed a systematic review and meta-analysis of the available literature to determine the rate of extension from limited colitis (proctitis or left-sided colitis) to more extensive disease and to assess the impact of known risk factors. We found that the overall rate of extension was 22.8% accounting for extension from E1 to E2 or E3, and E2 to E3. The pooled proportion for proximal extension was 17.8% at 5 years and 31% at 10 years. Rates of extension were higher in younger patients and in patients from North America compared to Europe and the rest of the world.
Previous estimates of disease extension have varied widely. In the IBSEN study 1 and others, one-fifth to one-third of patients with proctitis or left-sided colitis showed disease extension to the proximal colon. 14, 15, 20, 51 However, other studies have suggested much higher extension rates. Fumery et al. 60 in their review on the natural history of paediatric-onset ulcerative colitis, that included 26 population-based studies, found that paediatric-onset UC is characterised by a high rate of disease extension with most patients experiencing disease extension and about two-thirds of patients having pancolitis at the end of follow-up. Farmer et al. 17 reported that 53% of patients with UC had extension and a Danish inception cohort of 1161 UC patients demonstrated 53% of those with proctosigmoiditis had progression after 25 years. 5 The range of prior findings is likely due to differences in study design (retrospective vs prospective), varying durations of follow-up, ages included, treatments received and potentially environmental differences between different countries and regions. In addition, the way in which disease extent was ascertained varied, for example, some studies (particularly older ones) utilising barium enema or flexible sigmoidoscopy findings to define extension. Last, changes in disease management over time may also affect the cumulative rate of disease extension.
Our meta-analysis has shown that disease extension may occur any time after initial diagnosis with an increasing probability after the first decade of follow-up (31.1%) as reported by previous groups. 16 , 27 Moreover, we found that initial disease location does risk to extend to pancolitis, 15 although this has not been a consistent finding. 16 Our study confirmed that young age at diagnosis is a risk factor to predict extension in a patient with limited colitis. Few studies have investigated young age as a risk factor of extension over the time, and data are inconsistent. 5 Hochart et al. 61 reported a pooled proportion for colonic extension of 10% at 1 year, 45% at 5 years and 52% at 10 years in paediatric proctitis patients. The high likelihood of colonic extension suggests paediatric-onset ulcerative proctitis is not a minor, self-limited disease. Other studies have reported high rates of colonic extension in the paediatric population, ranging (B) UC overall rate of extension at 5 years (C) UC overall rate of extension at 10 years between 38% and 65%. 5, 12, 29, 42 For example, in an incidence cohort of 113 paediatric UC patients who were followed up for at least 2 years, disease extension was observed in 49% of patients. 42 The risk of extension seems highest within the first 5 years of follow-up, suggesting a role for monitoring paediatric patients closely after their diagnosis.
North American studies in our meta-analysis reported the highest rates of extension when compared to European and studies from other parts of the world. This finding may be due to a number of reasons. This may represent a real difference in disease behaviour based on geography which could be due to variation in environmental factors pre-disposing to UC extension. Alternatively, the time it takes to diagnose UC can vary from country to country and region to region. There may be a longer delay in diagnosis in North
American countries compared to Europe for example. If the diagnosis is significantly delayed and therefore treatment as well, this may pre-dispose patients to have progression of their UC. Geographic differences might also suffer from bias. Included studies follow patients for different periods of time, and some studies are following younger vs older patients whereas others are restricted to adults.
Furthermore, no adjustments are performed for different treatment patterns in the different countries.
There are several strengths and limitations of this meta-analysis.
Our extensive literature search allowed us to include 1772 UC patients for study. We also included both paediatric and adult patients and confirmed young age at diagnosis as a risk factor of extension. One of the major limitations of our study is that many included studies did not provide sufficient data on previously reported risk factors such as EIMs, pre-extension medications, smoking, severity of the disease or previously suggested risk factors such as delay in diagnosis of more than 6 months, a family history of inflammatory bowel disease, continuous disease activation within 6 months of the initial diagnosis, frequent relapses, severe bleeding, refractoriness to therapy, toxic colitis and inflammation of the appendiceal orifice. [15] [16] [17] [18] [19] [20] [21] [22] Of note, 12 of 30 studies included were in abstract form so information was limited.
Moreover, there are many inherent as well as technical difficulties in studies investigating factors related to UC proximal extension, as the methods used to determine disease extent over time have changed. 62, 63 In summary, the extent of colonic involvement in UC is an important clinical feature, because it serves as an indicator of the severity and activity of the disease, the type of treatment needed, as well as the future risk of high grade dysplasia and colorectal cancer. [3] [4] [5] [6] [7] [8] [9] In this meta-analysis we found that 22.8% of patients with limited colitis (E1 or E2) are at risk to progress to more extensive disease (E2 or E3), most frequently during the first 10 years after diagnosis. There also appears to be a higher risk of extension in 
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